

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Jerussi et al.

Docket No.

0701.196A


Application No. 10/663,173	Filing Date September 16, 2003	Examiner Brian J. Davis	Customer No. 02264	Group Art Unit 1621	Confirmation No. 2834
-------------------------------	-----------------------------------	----------------------------	-----------------------	------------------------	--------------------------

Invention: TREATMENT OF CNS DISORDERS WITH trans 4-(3,4- DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE AND ITS FORMAMIDE

COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.



CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	72 -	70 =	2	x \$50.00	\$100.00
INDEP. CLAIMS	11 -	14 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input checked="" type="checkbox"/>					\$360.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$460.00

No additional fee is required for amendment.

Please charge Deposit Account No. _____ in the amount of _____

A check in the amount of \$460.00 to cover the filing fee is enclosed.

The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 08-1935

- Any additional filing fees required under 37 C.F.R. 1.16.
- Any patent application processing fees under 37 CFR 1.17.

Payment by credit card. Form PTO-2038.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signature

Dated: January 24, 2006

Edward Timmer, Esq.
Registration No. 46,248
Heslin Rothenberg Farley & Mesiti P.C.
5 Columbia Circle
Albany, New York 12203
Telephone (518) 452-5600
Facsimile (518) 452-5579

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 24, 2006

(Date)

Signature of Person Mailing Correspondence

Edward Timmer

Typed or Printed Name of Person Mailing Correspondence

CC:



Docket No: 0701.196A

Jerussi et al.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>Applicant(s):</i>	Jerussi et al.	<i>Confirmation No.:</i>	2834
<i>Serial No.:</i>	10/663,173	<i>Group Art Unit:</i>	1621
<i>Filed:</i>	09/16/2003	<i>Examiner:</i>	Davis, Brian J.
<i>Docket No:</i>	0701.196A		
<i>Title:</i>	TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE AND ITS FORMAMIDE		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Mailing Date: January 24, 2006

RESPONSE

Dear Sir:

This is a Response to the Non-Final Office Action mailed on October 24, 2005. As the Action provided a three month period for response, a reply is due by January 24, 2006. Therefore, this Response is filed timely.

Claim amendments begin on page 2 of this paper.

Remarks begin on page 17 of this paper.

01/26/2006 YPOLITE1 00000082 10663173

01 FC:1202

100.00 OP
02 FC:1203